Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Iressa
Biotech
Pfizer’s dacomitinib bests Iressa in NSCLC OS showdown
The results of a phase 3 trial suggest dacomitinib is more effective than its aging rival.
Nick Paul Taylor
Jun 5, 2018 9:40am
AstraZeneca builds case for savolitinib combo
Oct 17, 2017 6:25am
ASCO: Chi-Med touts fruquintinib's phase 3 safety edge
Jun 5, 2017 6:24pm
Astellas scraps NSCLC program after look at phase 3 data
May 11, 2017 9:00am
AstraZeneca wants to advance lung cancer drug after hitting PhIII target
Jul 18, 2016 6:09am
